Dealmaking continued to be a key part of company strategies to address challenges facing the biopharma industry in 2025, including drug pricing pressures, a difficult biotech funding market and the need for large companies to replenish their pipelines ahead of loss of exclusivities on major products. Here, we cover mergers and acquisitions (M&As) and partnerships in the biopharma industry last year, as well as consumer and over-the-counter industries, drug delivery technologies, contract research, and clinical trial services, but excluding devices, diagnostics, research tools, animal health, and insurance.
Enjoying our latest content?
Log in or create an account to continue
Access the most recent journalism from Nature’s award-winning team
Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The authors declare no competing interests.